艾塞那肽(Exenatide) - 药物靶点：GLP-1R_在研适应症：2型糖尿病，糖尿病，肺性高血压_专利_临床

概要

基本信息

药物类型

合成多肽

别名

EXENATIDE SYNTHETIC、Exenatide (JAN/USAN/INN)、Exendin-4

+ [20]

靶点

GLP-1R

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

Amylin Pharmaceuticals, Inc.

在研机构

Aerami Therapeutics, Inc.

Icure Pharmaceutical Inc.Eli Lilly Nederland BV

+ [3]

非在研机构

Eli Lilly & Co.

AstraZeneca PLC

Intarcia Therapeutics, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2005-04-28),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)、优先审评 (中国)

登录后查看时间轴

序列信息

Sequence Code 751

来源: *****

关联

357

项与艾塞那肽相关的临床试验

NCT02586831 / Withdrawn临床1/2期IIT

A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes

To assess whether there is a difference in endogenous insulin secretion, measured as stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance test), at the 1 year visit, for study subjects receiving combinational therapy versus those receiving placebo. The study will also examine the effect of the proposed treatments on immunological outcomes, specifically proportion of regulatory T cells at the 1 year visit.

开始日期2025-01-01

申办/合作机构

University of Miami

[+1]

NCT05670379 / Not yet recruiting临床1期

A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant

The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.

开始日期2024-11-01

申办/合作机构

Vivani Medical, Inc.

[+1]

NCT05663515 / RecruitingN/A

EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an "intention-to-treat" approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a primary diagnosis of pancreatic cancer during follow-up.

开始日期2024-09-30

申办/合作机构

AstraZeneca PLC

[+1]

100 项与艾塞那肽相关的临床结果

登录后查看更多信息

100 项与艾塞那肽相关的转化医学

登录后查看更多信息

100 项与艾塞那肽相关的专利（医药）

登录后查看更多信息

4,050

项与艾塞那肽相关的文献（医药）

2025-02-01·Journal of Affective Disorders

A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders

Review

作者: Rhee, Taeho Greg ; Au, Hezekiah C.T. ; Au, Hezekiah C T ; Kwan, Angela T.H. ; Phan, Lee ; Rosenblat, Joshua D ; Teopiz, Kayla M ; Le, Gia Han ; McIntyre, Roger S. ; McIntyre, Roger S ; Kwan, Angela T H ; Rosenblat, Joshua D. ; Teopiz, Kayla M. ; Zheng, Yang Jing ; Ho, Roger ; Wong, Sabrina

INTRODUCTIONThe mechanistic role of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs) in modulating brain functional activity has been inadequately examined. Mental disorders are characterized by dysregulated functional connectivity in brain circuits that subserve phenomenology. We conducted a comprehensive synthesis of known effects of GLP-1 and GLP-1RAs on functional connectivity.METHODSWe conducted a systematic review examining studies that investigate changes in functional connectivity mediated by GLP-1 and GLP-1RAs in human adults. Relevant articles were retrieved from OVID (MedLine, Embase, AMED, PsychINFO, JBI EBP Database), PubMed, and Web of Science from database inception to April 26, 2024. Primary or secondary studies (n = 8) investigating the role of GLP-1 and GLP-1RAs on functional connectivity were included for analysis.RESULTSGLP-1 and GLP-1RAs modulate functional connectivity within the dorsal default mode network (DMN), visuospatial network, right frontal parietal network, and the salience network. GLP-1 agonism is also associated with decreased functional connectivity within the hypothalamus, lateral orbitofrontal cortex, and amygdala. Contrastingly, some GLP-1RAs (e.g. exenatide) increase functional connectivity in the hypothalamus, nucleus tractus solitarius, and thalamus. Moreover, liraglutide is associated with increased functional connectivity within the hippocampus in healthy individuals suggesting that GLP-1RAs may have differential effects on brain functional connectivity.DISCUSSIONWe observed that GLP-1 and GLP-1 RAs are associated with changes in functional connectivity known to subserve phenomenology of many mental disorders (e.g. anhedonia). Future research should aim to further examine neural circuits and networks affected by GLP-1 receptor activity and how they may affect cognitive and psychopathological domains in psychiatric disorders.

2025-01-01·Journal of Affective Disorders

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)

Article

作者: Mansur, Rodrigo B ; McIntyre, Roger S ; Teopiz, Kayla M ; Rosenblat, Joshua D. ; Rhee, Taeho Greg ; Cao, Bing ; Le, Gia Han ; Wong, Sabrina ; Kwan, Angela T H ; Teopiz, Kayla ; Kwan, Angela T.H. ; Ho, Roger ; Mansur, Rodrigo B. ; McIntyre, Roger S. ; Rosenblat, Joshua D

INTRODUCTIONReports of suicidality associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been reported to the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). We previously reported an increased reporting odds ratio (ROR) of some measures of suicidality with semaglutide and liraglutide using the FDA Adverse Event Reporting System (FAERS). Notwithstanding the increased ROR, causality between GLP-1 RAs exposure and any aspect of suicidality is not established.RESEARCH DESIGN AND METHODSThe analysis herein aims to extend a previous analysis of the FAERS by evaluating the ROR for suicidality reported to the World Health Organization (WHO) Pharmacovigilance Database (VigiBase). We aimed to characterize the ROR of suicidality associated with GLP-1 RAs, as extrapolated from spontaneous reports. As per our previous report, the ROR was considered significant when the lower limit of the 95 % confidence (CI) was >1.0.RESULTSWe searched VigiBase reports from inception to January 2024. The RORs for suicidal ideation were significantly increased for semaglutide (5.82), liraglutide (4.03) and tirzepatide (2.25). For "depression/suicidal", the ROR was significantly increased for semaglutide (14.74) and liraglutide (5.86); and for suicidal behaviour, the ROR was significantly increased for semaglutide (6.52) and liraglutide (3.90). However, for suicide attempts, the ROR was significantly decreased for semaglutide (0.11), dulaglutide (0.075), exenatide (0.047) and liraglutide (0.15). For completed suicide, the ROR was also significantly decreased for semaglutide (0.01), dulaglutide (0.003), exenatide (0.002) and liraglutide (0.008).CONCLUSIONUnlike our previous report with FAERS, a mixed pattern of ROR emerged in the WHO VigiBase with respect to suicidality and exposure to select GLP-RAs. Causation between GLP-1 RA exposure and suicidality (either increased or decreased) cannot be ascertained from ROR data.

2024-12-31·Journal of Obstetrics and Gynaecology

GLP1R boosts survival, migration and invasion of endometrial cancer cells and protects against ferroptotic cell death

Article

作者: Liu, Songjun ; Ruan, Fan ; Li, Wu ; Lyu, Wen ; Zhang, Xinmei

BACKGROUNDDespite the strong evidence concerning carcinogenic roles of glucagon-like peptide 1 receptor (GLP1R), the role of this gene in endometrial cancer (EC) remains elusive. This study investigated the properties of GLP1R on EC in vitro.METHODSThe expression of GLP1R in EC was detected by RT-qPCR, immunohistochemistry, and western blotting. Cell viability, cell cycle, apoptosis, migration, invasion and ferroptosis were assessed through CCK-8, flow cytometry, wound healing, transwell, DCFH-DA and western blotting, respectively.RESULTSWe found that GLP1R was up-regulated in EC than normal specimens. It had the highest expression in AN3CA cells. Cell viability, migration and invasion were significantly reduced, while cell cycle arrest and apoptosis were induced following GLP1R knockdown. The malignant biological behaviours of AN3CA cells were investigated when treated with exendin-4 (GLP1R agonist). Moreover, GLP1R lowered intracellular ROS level and expression of SLC7A11, and FTH1, but mitigated GPX4 expression in AN3CA cells.CONCLUSIONIn a word, GLP1R was up-regulated in EC and its up-regulation facilitated the proliferative and metastatic potentials, and protected cells from ferroptosis, thereby accelerating EC progression. These data emphasised the potency of GLP1R as a therapeutic agent against EC.

300

项与艾塞那肽相关的新闻（医药）

2024-11-15

·医学新视点

常用降糖、减肥药，还能用于戒酒？JAMA子刊：这两种药作用更佳

▎药明康德内容团队编辑喝酒伤身，这可不是一句空话。长期大量饮酒可导致酒精使用障碍的发生，患者对酒精使用的控制力削弱，导致生理依赖，耐受性增加以及心理、社会功能和身体的损害。相关研究显示，酒精使用障碍的终生患病率为9%，男性患病率是女性的48倍之多。心理社会支持治疗是酒精使用障碍治疗的基石，药物治疗数据比较有限，但整体也是有效的。既往动物实验发现，胰高血糖素样肽-1受体激动剂（GLP-1 RA）可减少酒精的使用，这提示GLP-1 RA或有潜力作为降低酒精危害的治疗方式。近日，JAMA Psychiatry发表一项研究，结果以简短报告的形式发布，表明GLP-1 RA中的司美格鲁肽和利拉鲁肽有助于减少酒精使用障碍患者的饮酒量，降低住院风险。截图来源：JAMA Psychiatry 这是一项观察性研究，纳入年龄16~64岁确诊为酒精使用障碍的患者22万多例，其中63.5%为男性，36.5%为女性，平均年龄40岁。中位随访8.8年间，其中6276例患者使用GLP-1 RA（主要为利拉鲁肽、艾塞那肽、度拉糖肽和司美格鲁肽），7.5万例患者接受酒精使用障碍药物（主要为disulfiram、acamprosate和纳曲酮）治疗。共有13万多（58.5%）的酒精使用障碍患者住院接受治疗。研究结果显示，接受GLP-1RA治疗的患者中，使用司美格鲁肽的患者风险最低，其中因酒精使用障碍住院风险降低了36%（aHR=0.64，95%CI：0.50~0.83），因任何物质使用障碍（指使用精神活性物质导致的任何精神障碍）住院风险降低了32%（aHR=0.68，95%CI：0.54~0.85）。其次是利拉鲁肽，其因酒精使用障碍住院风险降低了28%（aHR=0.72，95%CI：0.57~0.92），因任何物质使用障碍住院风险降低了22%（aHR=0.78，95%CI：0.64~0.97）。使用任何治疗酒精使用障碍的药物均可适当降低因酒精使用障碍住院风险和因任何物质使用障碍住院风险。 ▲使用不同药物的患者，因酒精使用障碍住院风险（A）和因任何物质使用障碍住院风险（B）差异（图片来源：参考文献[1]）此外，研究人员还发现，司美格鲁肽和利拉鲁肽可分别使因躯体症状住院风险降低22%（aHR=0.78，95%CI：0.68~0.90）和21%（aHR=0.79，95%CI：0.69~0.91），但并不能降低患者企图自杀的风险。研究第一作者兼通讯作者，来自东芬兰大学的Markku Lähteenvuo教授表示：“我们的研究结果表明，GLP-1RA不仅能够治疗糖尿病和肥胖，还可能有助于治疗酒精使用障碍和物质使用障碍，当然，这一发现仍需在随机对照试验中进一步验证”。点击文末“阅读原文/Read more”，即可访问JAMA Psychiatry官网阅读完整论文。推荐阅读欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。参考资料 [1]Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. Published online November 13, 2024. doi:10.1001/jamapsychiatry.2024.3599 [2] 王岚,王冉,王学义.酒精使用障碍的危害及风险[J].神经疾病与精神卫生，2024，22（4）：229-233. [3]University of Eastern Finland. Obesity-fighting drugs may reduce alcohol consumption in individuals with alcohol use disorder.13-Nov-2024.https://www.eurekalert.org/news-releases/1064676 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系。如有其他合作需求，请联系wuxi_media@wuxiapptec.com 分享，点赞，在看，传递医学新知

临床结果AHA会议

2024-11-15

·drugs

More Evidence That GLP-1 Meds Curb Alcohol Abuse

FRIDAY, Nov. 15, 2024 -- There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to curb problem drinking. Now, a new study out of Britain adds to that growing pile of evidence. “Our findings show that this type of diabetes medication shows promise in reducing alcohol consumption, potentially by targeting the brain’s reward centre," said study lead author Dr. Mohsen Subhani . The effect was especially pronounced in heavy drinkers who are also obese (a BMI over 30), added Subhani, who is a clinical assistant professor of gastroenterology at the University of Nottingham. The diabetes meds in question are called GLP-1 RAs (sometimes abbreviated as GLP-1s). They include diabetes meds like semaglutide (Ozempic and its weight-loss cousin, Wegovy), exenatide (Byetta), dulaglutide (Trulicity), and liraglutide (Victoza). The study was a kind of review: Researchers looked at collected data from prior studies. Subhani's team focused at results from six studies conducted before August of this year, including two "gold standard" clinical trials comprising a total of more than 88,000 people, about 44% of who were taking a GLP-1 medication. They tracked whether use of a GLP-1 med altered rates of alcohol use, alcohol-related health problems, hospital visits and "brain reactions to alcohol cues," according to a university news release. In one study, taking exenatide for six months didn't seem to affect alcohol issues for participants overall, but it did seem tied to reduced drinking for people who were also obese, the team said. Another trial found that people who took dulaglutide were 29% more likely to reduce their alcohol consumption than those on a placebo. And in the observational studies -- those that weren't prospective, clinical trials -- people displayed fewer health issues linked to alcohol if they were taking a GLP-1 versus other treatments, the research team said. The findings were published Nov. 14 in the journal eClinicalMedicine . All in all, "our findings suggest this could be a potential treatment option in the future for excessive alcohol use and subsequently could lead to a reduction in alcohol-related deaths,” Subhani said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2024-11-14

·研发客

净利下滑16%，石药的创新何时补位 | 江湖

// • 仍未有真正意义上的创新产品上市； • 新诺威在收购上频繁出手，意图越来越明确； • 新诺威2024Q3营业收入和净利润均同比下降； • 真正的创新重头戏应该是ADC。石药正在遭遇净利润的压力。2024年三季报的盈利预警显示，公司前三季度净利润约37.75亿人民币，同比下降16%，主要由于成药业务收入较去年同期减少约3%所致。中泰国际证券将其目标价下调至5.18港元。较早前的10月21日，瑞银减持石药1774万股。截至2024年，石药这艘“航母”在港股市场沉浮了30年。作为第一家被纳入恒生指数的医药企业，石药当下市值607亿港元，过去十年涨幅150%。另一边，2000年迈入A股市场的恒瑞医药，如今的市值已经突破3000亿，过去十年涨幅超过500%。也许是看到这种巨大的落差，石药决心要在A股市场拿到一张“创新药”的入场券。石药曾在2020年的一份公告中流露出科创板上市的想法，这应该是其进入A股的最初计划，后来被搁置的原因不得而知。而最近，子公司新诺威在收购上频繁出手，意图越来越明确。仿创老产品还没找到接替者如果单纯从已上市产品来看，石药在创新上的转身并没有预想中的那么敏捷。尽管目前公司在研的创新药项目近130项，但是短期之内，尚没有一款真正意义上的创新产品上市。 1997年，石家庄的四家药企“强强联合”成立了石药集团。蔡东晨当选为董事长，并一直执掌至今。在诸多以原料药起家的传统药企中，石药应该是最早迈入新药赛道的。 2005年，一款治疗急性缺血性脑卒中的产品恩必普（丁苯肽），成为脑血管领域第一个拥有知识产权的1类新药。由此奠定了石药在脑卒中领域的地位和研发布局。直到现在，恩必普仍然是石药的核心支柱产品。2023年销售额70亿元。由于其中一个重要含活性的化合物专利2032年才到期，恩必普还没有被纳入仿制药参比制剂。据中泰证券的研究报告透露，今年下半年以来恩必普受医保控费影响明显加剧，第三季度单季收入同比转跌，导致该板块前三季度的收入增速将从上半年的15%大幅缩小至4%。不过，专利到期的风险只是时间问题。石药正在准备一个接棒者。今年2月，三代溶栓药物明复乐（重组人TNK组织型纤溶酶原激活剂）适应症从心血管领域延伸到神经系统领域，获批用于急性缺血性卒中患者的溶栓治疗（发病<4.5h），为同类产品在中国首批。肿瘤产品作为石药的另一大支柱，升白药津优力和脂质体抗肿瘤药物多美素仍在集采的阴影之下，导致肿瘤业务收入整体下降明显。今年第三季度津优力与多美素受集采影响销售跌幅扩大，导致前三季度肿瘤药板块收入的同比跌幅从上半年的10%扩大至18%。 4亿研发费用输血之后 10月23日，新诺威公布了三季报。前三季度，公司实现营业收入14.79 亿元，同比下降23.66%，净利润1.39亿元，同比下降63.5%。除了主营业务咖啡因和保健品表现不佳之外，为巨石生物支付的研发费用也是影响业绩的重要原因。 2023年，新诺威完成了对巨石生物的收购。老瓶装新酒之后，新诺威更名为石药创新，并开始支撑起巨石生物的研发开支。2024年前三季度，巨石生物研发费用4.04亿元。2024年7~9月研发费用1.86亿元，较2023年7~9月同比增加 48.4%，较2024 年4~6月环比增加 56.6%。另一笔76亿的收购费用也将由新诺威买单。交易完成后，新诺威拥有石药百克100%股权。意味着，石药在A股市场将再度加入“创新药”基因。 CAR-T、ADC和mRNA：谁先兑现未来 CAR-T可能是石药在创新上的一张隐秘的王牌。10月25日，石药宣布，首款基于mRNA-LNP的CAR-T疗法SYS6020已获批在中国开展重症肌无力适应症的临床试验。此前，该产品已经获得多发性骨髓瘤以及系统性红斑狼疮的临床试验批准。实际上，从整体管线布局来看，石药的创新更像是一个保守的激进者。即将实现业绩贡献的两款创新产品是PD-1产品恩朗苏拜单抗、奥马珠单抗。10月8日，巨石研发的国产首仿奥马珠单抗，获批用于H1抗组胺药治疗后仍有症状的成人和12岁及以上青少年慢性自发性荨麻疹患者。此外，治疗哮喘的适应症也已申报上市。恩朗苏拜单抗也在今年6月获批上市，用于治疗至少一线含铂方案化疗失败的PD-L1表达阳性的复发或转移性宫颈癌患者。目前，这两个资产都在A股上市公司新诺威（石药创新）旗下。成立于2019年的巨石生物，曾经最大的光环是研发了首个国产获批上市的mRNA疫苗。尽管，新冠疫苗的价值已退出历史舞台，但巨石在mRNA疫苗领域的研发布局还在继续。今年上半年，公司的呼吸道合胞病毒mRNA疫苗获临床默认许可。此外，还有带状疱疹病毒及肿瘤等预防性和治疗性mRNA疫苗在研。真正的重头戏应该是ADC。去年ESMO上，巨石公布了HER2 ADC 产品DP303c治疗HER2表达晚期实体瘤的1期临床数据：在66例可评估疗效的乳腺癌患者中，客观缓解率（ORR）为51.5%，疾病控制率（DCR）为77.3%。目前，DP303c正在国内开展与恩美曲妥珠单抗（T-DM1）“头对头”的3期临床试验。还有另一款Nectin-4 ADC SYS6002，目前全球同类产品仅有Seagen/安斯泰来的Padcev上市。在2024年ASCO上，巨石公布了SYS6002的1期剂量递增数据。在≥1.2mg/kg剂量组宫颈癌患者中，ORR为43%，DCR为86%。除了宫颈癌之外，有分析师表示，看好SYS6002未来在尿路上皮癌一线治疗的潜力。去年，巨石生物与Corbus Pharmaceuticals就SYS6002达成开发及商业化订立独家授权协议。巨石生物将收取750万美元的首付款，以及最多5.55亿美元的潜在销售里程碑付款，总交易金额高达6.925亿美元。另有一款 CLDN18.2 ADC产品，在今年与Elevation Oncology达成研发与商业化协议，并获得2700万美元的首付款以及最多10.2亿美元的潜在销售里程碑付款。即将被装入上市公司的石药百克，手里的津优力在集采之下业绩疲软。另有几款在研产品似乎乏善可陈，分别是：围绕糖尿病和减重的重组胰高血糖素样肽-1 Fc融合蛋、2型糖尿病治疗的艾塞那肽、转移性结直肠癌的anti-EGFR 单抗、肿瘤骨转移及骨质疏松的anti-RANKL单抗。保守的激进者如果要说创新，石药近期和AZ达成交易的的一款小分子降脂药物YS2302018，看起来更有潜力。这是一款口服脂蛋白(a)抑制剂，用于多种心血管疾病的单一疗法或联合疗法，包括与口服小分子PCSK9抑制剂AZD0780联用。脂蛋白(Lp(a))被视为下一代降脂重磅药物的潜力靶点，诺华旗下的Pelacarsen已进入临床3期。石药的这款YS2302018，目前处在临床前阶段，是由AI驱动的小分子药物设计平台发现。对于并不缺钱的石药来说，AZ的1亿美元首付款真的非常有吸引力吗？或者说，石药在临床前的创新产品研发上还有一些保守。近期，刘勇军博士出任石药研发总裁，或许会给石药在创新上带来新的计划和决心。编辑 | 姚嘉 yao.jia@PharmaDJ.com 总第2246期访问研发客网站，深度报道和每日新闻抢鲜看 www.PharmaDJ.com

专利到期抗体药物偶联物并购

100 项与艾塞那肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04121	艾塞那肽	A10BJ01	DB01276

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	美国	AstraZeneca AB	2005-04-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床前	美国	AstraZeneca PLC	2016-03-22
心脏衰竭	临床前	法国	Eli Lilly & Co.	2015-05-01
心脏衰竭	临床前	法国	AstraZeneca PLC	2015-05-01
高血糖	临床前	法国	AstraZeneca PLC	2015-01-01
高血糖	临床前	法国	Eli Lilly & Co.	2015-01-01
冠心病	临床前	捷克	Eli Lilly & Co.	2011-06-01
左心室功能不全	临床前	捷克	Eli Lilly & Co.	2011-06-01
低血糖	临床前	德国	AstraZeneca PLC	2007-02-01
2型糖尿病	临床前	匈牙利	Eli Lilly & Co.	2002-08-01
2型糖尿病	临床前	匈牙利	Eli Lilly & Co.	2002-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01107717 (EDICT, CTgov)	临床4期	2型糖尿病	318	exenatide+pioglitazone+metformin (Triple Therapy)	憲蓋願顧鬱築築積醖襯(醖獵夢壓積艱醖膚憲糧) = 製顧築鹹鹽衊憲齋願醖廠窪觸築艱繭壓廠膚願 (範製構糧製鏇鏇淵觸願, 淵廠鹹襯築餘餘膚鑰築 ~ 鹽範窪齋鹽獵襯觸鬱蓋) 更多	-	2024-09-05
				glargine+metformin+glyburide (Conventional Therapy)	憲蓋願顧鬱築築積醖襯(醖獵夢壓積艱醖膚憲糧) = 獵夢顧廠構夢獵繭選鑰廠窪觸築艱繭壓廠膚願 (範製構糧製鏇鏇淵觸願, 鑰夢鬱憲獵積鬱製積衊 ~ 餘餘願製顧鹹窪願簾壓) 更多
NCT03029351 (1981, CTgov)	临床4期	肾脏疾病 \| 2型糖尿病 \| 蛋白尿	15	Exenatide Extended Release for Inj Susp 2 MG (Exenatide Extended Release)	築繭網願鏇鹽壓獵選鏇(網積憲膚齋夢範顧鬱鹽) = 餘齋壓襯構淵糧顧憲觸選構憲鏇蓋醖蓋鏇鹽遞 (獵鬱鏇淵簾齋築簾遞憲, 艱繭鏇膚餘簾鹽鏇網鹹 ~ 齋積憲築構窪積獵鏇鏇) 更多	-	2024-04-16
				Placebo (Placebo)	築繭網願鏇鹽壓獵選鏇(網積憲膚齋夢範顧鬱鹽) = 積觸憲願醖顧糧廠壓鬱選構憲鏇蓋醖蓋鏇鹽遞 (獵鬱鏇淵簾齋築簾遞憲, 夢願網積鏇製顧淵餘膚 ~ 積憲蓋遞繭壓淵製鹽製) 更多
NCT02962492 (CTgov)	N/A	1型糖尿病	70	Placebo (Placebo Arm:)	選蓋築膚鏇鹽積鹽鏇壓(積遞鹽艱築廠膚餘夢鬱) = 襯艱觸糧遞願壓觸醖壓構窪夢願餘顧鑰簾鹽蓋 (觸膚範鏇鏇鹹鏇網廠繭, 範積衊顧廠簾齋夢夢製 ~ 蓋築淵憲簾衊艱蓋襯糧) 更多	-	2024-02-29
				Dapagliflozin (Dapagliflozin Arm:)	選蓋築膚鏇鹽積鹽鏇壓(積遞鹽艱築廠膚餘夢鬱) = 積醖積繭鹹膚選鏇憲製構窪夢願餘顧鑰簾鹽蓋 (觸膚範鏇鏇鹹鏇網廠繭, 艱構遞遞廠膚壓壓構積 ~ 鬱壓顧憲構糧鹹範窪襯) 更多
NCT01524705 (FLAT-SUGAR, CTgov)	临床4期	2型糖尿病	102	Insulin Glargine+Exenatide+Metformin	餘範選壓餘顧廠鏇獵繭(夢獵醖製鏇餘蓋繭淵遞) = 醖齋廠願鬱膚鹹憲構膚餘鏇鬱艱鹹蓋觸積壓襯 (網醖築觸艱鹽積蓋遞鬱, 選衊憲窪簾廠積壓夢襯 ~ 鏇鑰遞糧艱鏇顧範襯淵) 更多	-	2023-12-29
NCT02621489 (Rebuild Study, Pubmed \| Cardiovasc Diabetol)	临床4期	2型糖尿病 GLP-1R	38	Exenatide + standard treatment	網築製鏇廠顧壓壓膚鹹(醖鹹顧遞壓獵獵膚糧遞) = 廠製艱鑰蓋壓窪齋廠範繭襯憲鹹壓憲觸製憲鏇 (繭鏇鑰蓋衊顧蓋顧遞獵 )	不佳	2023-12-08
				Standard treatment alone	網築製鏇廠顧壓壓膚鹹(醖鹹顧遞壓獵獵膚糧遞) = 醖觸觸鏇積蓋築簾構齋繭襯憲鹹壓憲觸製憲鏇 (繭鏇鑰蓋衊顧蓋顧遞獵 )
NCT04307797 (EASD2023)	临床4期	2型糖尿病	8	Saline	(鹹鑰窪餘窪壓鏇糧範壓) = There were no adverse events 齋鬱艱築醖糧顧積繭構 (衊糧糧簾蓋網醖淵鹽膚 ) 更多	不佳	2023-10-04
				Glucagon
NCT02621489 (Rebuild study, EASD2023)	临床4期	2型糖尿病 HbA1c	38	Exenatide	獵齋窪選窪獵獵願艱廠(顧顧壓餘獵繭鏇鹹窪獵) = 鹽築範艱憲鑰簾觸選蓋鏇顧淵夢築觸襯膚蓋獵 (鑰觸遞鹽蓋簾夢艱願鏇 ) 更多	不佳	2023-10-04
				Standard treatment	獵齋窪選窪獵獵願艱廠(顧顧壓餘獵繭鏇鹹窪獵) = 醖積築醖鏇衊壓壓選衊鏇顧淵夢築觸襯膚蓋獵 (鑰觸遞鹽蓋簾夢艱願鏇 ) 更多
Rebuild study (ESC2023)	N/A	非胰岛素依赖型糖尿病2	38	Bydureon	製鑰窪範艱願糧蓋簾窪(網膚憲廠醖衊觸願夢鏇) = 鬱簾餘蓋鑰廠製獵膚遞構糧窪淵顧鬱構廠醖衊 (顧顧膚艱簾膚齋壓願糧 ) 更多	-	2023-08-25
				Standard treatment	製鑰窪範艱願糧蓋簾窪(網膚憲廠醖衊觸願夢鏇) = 餘積簾顧糧積窪衊製窪構糧窪淵顧鬱構廠醖衊 (顧顧膚艱簾膚齋壓願糧 ) 更多
NCT03331289 (CTgov)	临床4期	2型糖尿病	107	Placebo (Placebo)	觸選餘窪鏇蓋積獵積繭(觸廠鹽糧淵觸醖製襯壓) = 淵構鏇鏇夢夢鹹製膚艱築鏇繭膚衊蓋膚膚憲遞 (齋齋膚範艱積構醖窪艱, 範遞膚積窪獵願願觸齋 ~ 鏇衊鏇鏇繭構獵繭選觸) 更多	-	2023-07-24
				Exenatide (Exenatide)	觸選餘窪鏇蓋積獵積繭(觸廠鹽糧淵觸醖製襯壓) = 淵簾夢顧鏇簾顧遞蓋繭築鏇繭膚衊蓋膚膚憲遞 (齋齋膚範艱積構醖窪艱, 糧糧鑰構餘願獵觸觸夢 ~ 淵窪衊選艱積鹽簾襯觸) 更多
NCT02981069 (CTgov)	临床4期	2型糖尿病	90	Dapagliflozin (Dapagliflozin)	願簾簾鏇鹹鏇餘顧獵窪(觸簾遞鏇膚觸顧鏇廠壓) = 餘構膚膚衊鑰鑰醖壓醖壓網範廠襯網製窪襯淵 (窪顧艱範鬱糧獵蓋鹽遞, 繭積製醖網鹽糧齋遞選 ~ 廠鑰糧憲蓋壓繭淵遞艱) 更多	-	2023-07-20
				Placebo (Placebo)	願簾簾鏇鹹鏇餘顧獵窪(觸簾遞鏇膚觸顧鏇廠壓) = 鑰鏇構壓窪夢艱築簾觸壓網範廠襯網製窪襯淵 (窪顧艱範鬱糧獵蓋鹽遞, 醖鬱糧積簾蓋醖壓齋簾 ~ 齋窪願築餘繭遞餘獵築) 更多